Israel based Gordian Surgical, a portfolio company of Trendlines Medical, has raised nearly $1 million, including an investment from Virtus Inspire Ventures, a Chinese venture capital firm. Gordian intends to use the funds to complete American (FDA) and European (CE) regulatory processes, start first-in-man (clinical) trials, and prepare for market penetration.
The "two-in-one" trocar inserts sutures into the tissue surrounding the incision at the beginning of the procedure and anchors them to stay in place throughout the operation. The built-in closure mechanism enables surgeons to easily close the sutures when the trocar is removed at the end of the procedure.
Mr Zvi Pe'er, CEO, Gordian Surgical, remarked, "I am extremely pleased by the growing level of interest in our company and technology. This investment by a VC and senior surgeons is evidence of the confidence in our team and in the market potential of our products." Mr Eran Feldhay, CEO, Trendlines Medical, added, "We are very proud of Gordian's progress as a company that is developing a simple, cost-saving trocar to reduce the risks and complications of laparoscopic procedures and has attracted global interest from investors and industry leaders."